Beth L Laube1, Kathryn A Carson2, Christopher M Evans3, Vanessa L Richardson3, Gail Sharpless1, Pamela L Zeitlin4, Peter J Mogayzel1. 1. Department of Pediatrics, Johns Hopkins Medical Institutions, Baltimore, Maryland. 2. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland. 3. Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado. 4. Department of Pediatrics, National Jewish Health, Denver, Colorado.
Abstract
OBJECTIVES: (a) To quantify changes in mucociliary clearance (MCC) over time in children with cystic fibrosis (CF) and the relationship between MCC and rate of infection with Pseudomonas aeruginosa (PA); (b) to determine the impact of MCC on the evolution of CF lung disease; and (c) to explore the role of mucus composition as a determinant of MCC. METHODS: Children with CF, who had previously undergone an MCC measurement (visit 1), underwent the following tests 3 to 10 years later: (a) second MCC measurement (visit 2); (b) multiple breath washout to assess ventilation inhomogeneity, expressed as lung clearance index (LCI); (c) high resolution computed tomography lung scan (HRCT); and (d) induced sputum test. Number of PA + cultures/year between visits was documented and mucus dry weight was quantified in the children and adult controls. RESULTS: Nineteen children completed both visits. Median time between visits was 4.6 years. Clearance declined 30% between visits. Lower MCC on visit 2 was associated with more PA+ cultures/year between visits. Lower MCC values on visit 1 were associated with higher LCI values and higher HRCT scores on visit 2. Mucus dry weight was significantly higher in children with CF compared with controls. Higher dry weights were associated with lower MCC. CONCLUSIONS: Mucociliary clearance declines significantly over time in children with CF. The decline is associated with PA infection rate and is affected by mucus composition. Children with early slowing of MCC appear to be at risk for developing ventilation inhomogeneity and parenchymal lung damage when they are older.
OBJECTIVES: (a) To quantify changes in mucociliary clearance (MCC) over time in children with cystic fibrosis (CF) and the relationship between MCC and rate of infection with Pseudomonas aeruginosa (PA); (b) to determine the impact of MCC on the evolution of CF lung disease; and (c) to explore the role of mucus composition as a determinant of MCC. METHODS: Children with CF, who had previously undergone an MCC measurement (visit 1), underwent the following tests 3 to 10 years later: (a) second MCC measurement (visit 2); (b) multiple breath washout to assess ventilation inhomogeneity, expressed as lung clearance index (LCI); (c) high resolution computed tomography lung scan (HRCT); and (d) induced sputum test. Number of PA + cultures/year between visits was documented and mucus dry weight was quantified in the children and adult controls. RESULTS: Nineteen children completed both visits. Median time between visits was 4.6 years. Clearance declined 30% between visits. Lower MCC on visit 2 was associated with more PA+ cultures/year between visits. Lower MCC values on visit 1 were associated with higher LCI values and higher HRCT scores on visit 2. Mucus dry weight was significantly higher in children with CF compared with controls. Higher dry weights were associated with lower MCC. CONCLUSIONS: Mucociliary clearance declines significantly over time in children with CF. The decline is associated with PA infection rate and is affected by mucus composition. Children with early slowing of MCC appear to be at risk for developing ventilation inhomogeneity and parenchymal lung damage when they are older.
Authors: Hirotoshi Matsui; Margrith W Verghese; Mehmet Kesimer; Ute E Schwab; Scott H Randell; John K Sheehan; Barbara R Grubb; Richard C Boucher Journal: J Immunol Date: 2005-07-15 Impact factor: 5.422
Authors: William D Bennett; Beth L Laube; Timothy Corcoran; Kirby Zeman; Gail Sharpless; Kristina Thomas; Jihong Wu; Peter J Mogayzel; Joseph Pilewski; Scott Donaldson Journal: J Aerosol Med Pulm Drug Deliv Date: 2013-03-21 Impact factor: 2.849
Authors: Paul D Robinson; Philipp Latzin; Sylvia Verbanck; Graham L Hall; Alexander Horsley; Monika Gappa; Cindy Thamrin; Hubertus G M Arets; Paul Aurora; Susanne I Fuchs; Gregory G King; Sooky Lum; Kenneth Macleod; Manuel Paiva; Jane J Pillow; Sarath Ranganathan; Sarah Ranganathan; Felix Ratjen; Florian Singer; Samatha Sonnappa; Janet Stocks; Padmaja Subbarao; Bruce R Thompson; Per M Gustafsson Journal: Eur Respir J Date: 2013-02-08 Impact factor: 16.671
Authors: Barbara R Grubb; Alessandra Livraghi-Butrico; Troy D Rogers; Weining Yin; Brian Button; Lawrence E Ostrowski Journal: Am J Physiol Lung Cell Mol Physiol Date: 2016-03-11 Impact factor: 5.464
Authors: Richard Kraemer; Andrea Blum; Andreas Schibler; Roland A Ammann; Sabina Gallati Journal: Am J Respir Crit Care Med Date: 2004-11-05 Impact factor: 21.405
Authors: Ashley G Henderson; Camille Ehre; Brian Button; Lubna H Abdullah; Li-Heng Cai; Margaret W Leigh; Genevieve C DeMaria; Hiro Matsui; Scott H Donaldson; C William Davis; John K Sheehan; Richard C Boucher; Mehmet Kesimer Journal: J Clin Invest Date: 2014-06-02 Impact factor: 14.808
Authors: Beth L Laube; Kathryn A Carson; Christopher M Evans; Melis A Aksit; Joseph M Collaco; Vanessa L Richardson; Gail Sharpless; Pamela L Zeitlin; Garry R Cutting; Peter J Mogayzel Journal: Pediatr Res Date: 2021-03-22 Impact factor: 3.756